Pfizer executives said most patients experienced few or mild side effects, with gastrointestinal events largely limited ​to ...

Pfizer (PFE) stock is in focus as mid-stage trial data support a once-monthly dosing regimen for GLP-1 therapy berobenatide.

Pfizer revealed data on its new obesity drug berobenatide, following its acquisition of Metsera. The monthly dose showed ...

Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF’3944), an ...

NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and ...

On the heels of a strong showing for the drug earlier this year, Pfizer is padding the case for the GLP-1 receptor agonist it ...

Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

The pharma company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry leader.

PHILADELPHIA -- To help fend off another wave of Covid-19, people will need a fourth dose of vaccine, Pfizer CEO Albert Bourla said Sunday. "Many variants are coming, and Omicron was the first one ...

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

In a recent study published in The Lancet Regional Health Western Pacific, researchers compare the immunogenicity, reactogenicity, and safety of a half-dose Pfizer-BioNTech BNT162b2 coronavirus ...